Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Syndexa: De-stressing diabetes

Most marketed diabetes drugs, such as the insulin-sensitizing thiazolidinediones, address the disease's symptoms but have no meaningful impact on progression. Syndexa Pharmaceuticals Corp. thinks its small molecule programs targeting c-jun N-terminal kinase and endoplasmic reticulum stress will address the underlying cause of metabolic diseases. The company hopes to have a candidate from one of the two programs in human testing to treat Type II

Read the full 642 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE